iCAD,
Inc. (Nasdaq:ICAD), industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that Chief
Financial Officer (CFO), Kevin Burns, has been named iCAD’s Chief
Operating Officer (COO). In this newly-created position, Burns will lead
and manage all operational functions within the Company in addition to
continuing his role as CFO.
“Kevin has made many significant contributions to iCAD and I am
confident he will continue to guide the Company in meeting its short and
long term growth and business goals. During his tenure as CFO, the
Company’s financial performance has improved through increasing
efficiencies and maximizing investments, while reducing operating
expenses,” said Ken Ferry, President and CEO of iCAD. “Kevin has played
a critical role in developing our strategic partnerships, which have
resulted in a stronger overall growth trajectory in our cancer detection
and Xoft therapy businesses. We expect his expanded executive role will
enhance our continued success.”
“I’m looking forward to taking on these additional responsibilities at
iCAD and continuing to work closely with our executive team, as we
advance the Company to its next level of growth,” said Kevin Burns, COO
and CFO of iCAD. “This is an exciting time for our Company, as we
successfully broaden our product offerings, build our customer base and
expand our reach through technology innovation and strategic
partnerships.”
About iCAD, Inc.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD)
technologies, advanced image analysis, workflow solutions and radiation
therapies for the early identification and treatment of common cancers.
iCAD offers a comprehensive range of high-performance, upgradeable CAD
solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate
cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft
System, offers radiation treatment for early-stage breast cancer that
can be administered in the form of Intraoperative Radiation Therapy or
accelerated partial breast irradiation. The Xoft System is also cleared
for the treatment of non-melanoma skin cancer and gynecological cancers.
For more information, call (877) iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s ability to defend itself in litigation matters, the
risks relating to the Company’s acquisition of Xoft including, the
expected benefits of the acquisition may not be achieved in a timely
manner, or at all; the Xoft business operations may not be successfully
integrated with iCAD’s and iCAD may be unable to achieve the expected
synergies, business and strategic objectives following the transaction,
the risks of uncertainty of patent protection; the impact of supply and
manufacturing constraints or difficulties; product market acceptance;
possible technological obsolescence; increased competition; customer
concentration; and other risks detailed in the Company’s filings with
the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”,
and similar expressions identify forward-looking statements. Readers are
cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made. The
Company is under no obligation to provide any updates to any information
contained in this release. For additional disclosure regarding these and
other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on
the Investors section of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov
Copyright Business Wire 2013